NAA Services for Anti-CD44 Antibody

The natural autoantibodies (NAAs) against tumor-associated antigens in the sera or tissue of nasopharyngeal carcinoma (NPC) patients could be used as the basis for a screening test for NPC. Creative Biolabs now offers a comprehensive set of NAA services about autoantibody against CD44, an identified surface marker of NPC, armed with extensive experience and advanced platforms.

Background of CD44

CD44 is a cell-surface glycoprotein extensively distributed that functions in many biologic processes, including cell-cell interactions, cell adhesion, migration, etc. CD44 consists of extracellular, transmembrane and intercellular domains, and acts mainly as the receptor for hyaluronic acid. CD44 molecule mainly regulates many pivotal bio-functions, including hyaluronic acid metabolism, lymphocytes activation, hematopoiesis, and cytokines release in normal tissues. Specific alternative splicing variants of CD44 are often detected in cancer cells. It is CD44, especially the variant isoforms of CD44, has been revealed to be biomarkers of cancer stem cells, a subpopulation of cells within a tumor appears to have the exclusive ability to initiate tumors, self-renew, and differentiate. Emerging evidence has indicated that CD44 is a prognostic indicator in several carcinomas and soon recognized to be able to initiate the metastatic spread of tumor cells.

Fig.1 Structure and function of CD44. (Wang, et al., 2018)Fig.1 CD44 molecules, prominent ligands, and associated molecules.1

The Role of Anti-CD44 Antibody in Nasopharyngeal Carcinoma

NPC is a unique cancer of head and neck, commonly arising from the epithelial lining of the lateral wall of the nasopharynx, particularly at the fossa of Rosenmüller and superior posterior wall. The incidence of this tumor is common in southern China and Southeast Asia. High expression of variant 6 isoform of CD44 (CD44v6) is demonstrated to associate with resistance to concurrent chemoradiotherapy at the primary NPC site and high expression of CD44v3 in NPC is associated with lower disease-specific survival rate.

Fig.2 CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma. (Lun, et al., 2012)Fig.2 Sphere-forming cells with stem cell-like properties in EBV-positive NPC express cell surface marker CD44.2

Several NPC tumor markers had been identified but a reliable diagnostic assay for the early detection of NPC is scarce and highly needed. By taking full advantage of the fact that the immune system often produces antibodies against mutated or aberrantly expressed proteins, scientists have identified multiple autoantibodies that could be used as markers for the detection of NPC. The anti-CD44 antibody is one of these identified autoantibodies that can be used to predict the clinical stages of NPC.

What We Can Do About NAA?

Testing a full panel of NAAs specific for NPC will be an important part of assay validation and clinical diagnosis. In NPC, anti-CD44 NAA has been confirmed as a biomarker. As a long-term expert in cancer disease diagnosis, Creative Biolabs owns lots of scientists who are proficient in NAA analysis and detection. Our professional scientists are pleased to provide the custom services against CD44 marker to diagnose NPC disease sensitively. If you are interested in our extensive NAA services, please contact us for more details.

References

  1. Wang, Zhe, et al. "CD44/CD44v6 a reliable companion in cancer-initiating cell maintenance and tumor progression." Frontiers in cell and developmental biology 6 (2018): 97.
  2. Lun, Samantha Wei-Man, et al. "CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma." PloS one 7.12 (2012): e52426.
For Research Use Only | Not For Clinical Use

Related Services:

Products:

Resource:

Applications:

Online Inquiry
Inquiry